Corrigendum to: Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study (Current Medical Research and Opinion, (2014), 30, 10, (2069-2083), 10.1185/03007995.2014.928275);Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: A phase III, double-blind, randomized withdrawal, placebo-controlled study

Current Medical Research and Opinion

Volumn 30, Issue 10, 2014, Pages 2069-2083

  Arnold, Lesley M ^a   Arsenault, Pierre ^b   Huffman, Cynthia ^c   Patrick, Jeffrey L ^d   Messig, Michael ^d   Chew, Marci L ^d   Sanin, Luis ^d   Scavone, Joseph M ^d   Pauer, Lynne ^d   Clair, Andrew G ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c Meridien Research   (United States)

^d PFIZER INC   (United States)

Author keywords

Controlled release; Fibromyalgia; Pain; Pregabalin; Randomized withdrawal; Sleep

Indexed keywords

ACETYLSALICYLIC ACID; PARACETAMOL; PREGABALIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DELAYED RELEASE FORMULATION;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHIROPRACTIC; CLINICAL EVALUATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; FUNCTIONAL STATUS; GLOBAL ASSESSMENT OF FUNCTIONING; GLOSSITIS; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; LOSS OF THERAPEUTIC RESPONSE; MAJOR CLINICAL STUDY; MALE; MASSAGE; MIDDLE AGED; MULTICENTER STUDY; PAIN ASSESSMENT; PAIN SEVERITY; PATIENT SATISFACTION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PHYSIOTHERAPY; PNEUMONIA; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SLEEP; SOMNOLENCE; SUICIDAL IDEATION; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA; ADMINISTRATION AND DOSAGE; ANALGESIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; DOSE CALCULATION; PAIN MEASUREMENT; PATHOPHYSIOLOGY; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG DOSAGE CALCULATIONS; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PAIN MANAGEMENT; PAIN MEASUREMENT; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84906938859     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1292446     Document Type: Erratum

References (32)

1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10
2. Lawrence RC, Felson DT, Helmick CG, et al National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
3. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39:448-53
4. Adams E, Daniel S, Chandran A, et al. A population-based survey and physician assessment of the characteristics and prevalence of fibromyalgia. Arthritis Rheum 2013;65(10 Suppl):S55
5. Arnold LM, Clauw DJ, Dunegan LJ, et al. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc 2012;87:488-96
6. Clauw DJ, Arnold LM, McCarberg BH. The science of fibromyalgia. Mayo Clin Proc 2011;86:907-11
7. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-50
8. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
9. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
10. Pauer L, Winkelmann A, Arsenault P, et al; on behalf of the A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-52
11. Crofford LJ, Rowbotham MC, Mease PJ, et al; and the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
12. Lyrica (pregabalin) capsules [prescribing information], 2012. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=561 [Last accessed 27 December 2013]
13. World Health Organization. Adherence to long-term therapies - evidence for action, 2003. Available at: http://apps.who.int/medicinedocs/en/d/Js4883e/6.1.html [Last accessed 7 January 2014]
14. Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013;7:419-34
15. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18:527-39
16. New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease, 2009. Available at: http://www.nehi.net/writable/publication-files/file/pa-issue-brief-final.pdf [Last accessed 19 May 2014]
17. Chew M, Plotka A, Alvey C, et al. Effect of food and dose on pregabalin controlled release pharmacokinetics in healthy volunteers. J Pain 2013;14:S66
18. Chew ML, Plotka A, Alvey CW et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: Effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig 2014, DOI 10.1007/s40261-014-0211-4. [epub ahead of print]
19. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
20. Williams DA, Arnold LM. Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S86-97
21. Assumpc¸ão A, Pagano T, Matsutani LA, et al. Quality of life and discriminating power of two questionnaires in fibromyalgia patients: Fibromyalgia Impact Questionnaire and Medical Outcomes Study 36-Item Short-Form Health Survey. Rev Bras Fisioter 2010;14:284-9
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
23. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
24. Arnold LM, Zlateva G, Sadosky A, et al. Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 2011;12:260-7
25. Pleil AM, Coyne KS, Reese PR, et al. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue - the BSW. Value Health 2005;8(Suppl 1):S25-34
26. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
27. Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain 2014;30:379-90
28. Nasser K, Kivitz AJ, Maricic MJ, et al. Twice daily vs once nightly dosing of pregabalin for fibromyalgia: a double-blind, randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken) 2014;66:293-300
29. McQuay HJ, Derry S, Moore RA, et al. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 2008;135:217-20
30. Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain 2009;25:797-807
31. Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain 2008;136:232-4
32. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21